Publikationen von Kinga Penzes

Szokol, B.; Gyulavari, P.; Kurko, I.; Baska, F.; Szantai-Kis, C.; Greff, Z.; Örfi, Z.; Petak, I.; Penzes, K.; Torka, R. et al.; Ullrich, A.; Örfi, L.; Vantus, T.; Keri, G.: Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors. ACS MEDICINAL CHEMISTRY LETTERS 5 (4), S. 298 - 303 (2014)

Torka, R.; Penzes, K.; Gusenbauer, S.; Baumann, C.; Szabadkai, I.; Orfi, L.; Keri, G.; Ullrich, A.: Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy. NEOPLASIA 16 (4), S. 301 - 318 (2014)

Penzes, K.; Baumann, C.; Szabadkai, I.; Orfi, L.; Keri, G.; Ullrich, A.; Torka, R.: Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. CANCER BIOLOGY & THERAPY 15 (11), S. 1571 - 1582 (2014)

Belle, R.; Baska, F.; Orfi, Z.; Szantai-Kis, C.; Sipos, A.; Breza, N.; Borbely, G.; Penzes, K.; Orfi, L.; Keri, G.: Characterization of p53 activator compounds which inhibit a survival factor kinase as well. FEBS Journal 279 (Suppl. 1 Sp. Iss.), S. 179 - 179 (2012)

Torka, R.; Penzes, K.; Baumann, C.; Gusenbauer, S.; Szabadkai, I.; Orfi, L.; Keri, G.; Ullrich, A.: Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors - suggestion of combination therapy. In EUROPEAN JOURNAL OF CANCER, 50 (Suppl. 5), 801, S. S193 - S194. ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND (2014)